These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12382520)

  • 1. Advances in diagnosis and management of oligodendroglioma.
    Hussein MR; Baidas S
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):520-8. PubMed ID: 12382520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of oligodendroglial tumours: current developments.
    van den Bent MJ
    Forum (Genova); 2000; 10(2):108-18. PubMed ID: 10875973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives for the diagnosis and treatment of oligodendroglioma.
    van den Bent MJ
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):348-56. PubMed ID: 12113102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligodendroglioma.
    Van den Bent MJ; Reni M; Gatta G; Vecht C
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):262-72. PubMed ID: 18272388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic oligodendroglioma and oligoastrocytoma.
    van den Bent MJ
    Neurol Clin; 2007 Nov; 25(4):1089-109, ix-x. PubMed ID: 17964027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
    Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".
    Sasaki H; Zlatescu MC; Betensky RA; Johnk LB; Cutone AN; Cairncross JG; Louis DN
    J Neuropathol Exp Neurol; 2002 Jan; 61(1):58-63. PubMed ID: 11829344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligodendrogliomas: molecular biology and treatment.
    Bromberg JE; van den Bent MJ
    Oncologist; 2009 Feb; 14(2):155-63. PubMed ID: 19182242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
    Cairncross G; Jenkins R
    Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas.
    Kitange G; Misra A; Law M; Passe S; Kollmeyer TM; Maurer M; Ballman K; Feuerstein BG; Jenkins RB
    Genes Chromosomes Cancer; 2005 Jan; 42(1):68-77. PubMed ID: 15472895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
    Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature.
    Bruggers C; White K; Zhou H; Chen Z
    J Pediatr Hematol Oncol; 2007 May; 29(5):319-22. PubMed ID: 17483710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.
    Jaeckle KA; Ballman KV; Rao RD; Jenkins RB; Buckner JC
    J Clin Oncol; 2006 Mar; 24(8):1246-52. PubMed ID: 16525179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing management of low-grade astrocytomas and oligodendrogliomas.
    Agulnik M; Mason WP
    Hematol Oncol Clin North Am; 2006 Dec; 20(6):1249-66. PubMed ID: 17113461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
    Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
    Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
    Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C
    Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
    Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
    Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.